Utilities and disutilities for attributes of injectable treatments for type 2 diabetes (Q48864523)

16 February 2018

title

Utilities and disutilities for attributes of injectable treatments for type 2 diabetes (English)

1 reference

16 February 2018

0 references

Kristina S Boye

1

1 reference

16 February 2018

Louis S Matza

2

1 reference

16 February 2018

Kimberly N Walter

3

1 reference

16 February 2018

Kate Van Brunt

4

1 reference

16 February 2018

Andrew C Palsgrove

5

1 reference

16 February 2018

Aodan Tynan

6

1 reference

16 February 2018

publication date

12 March 2010

1 reference

16 February 2018

The European Journal of Health Economics

published in

1 reference

16 February 2018

volume

12

1 reference

16 February 2018

issue

3

1 reference

16 February 2018

page(s)

219-230

1 reference

16 February 2018

GLP-1 based therapy for type 2 diabetes

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS10198-010-0224-8

Targeting Incretins in Type 2 Diabetes: Role of GLP-1 Receptor Agonists and DPP-4 Inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-010-0224-8

Recent advances in the management of type 2 diabetes mellitus: a review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-010-0224-8

Measurement of health state utilities for economic appraisal

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-010-0224-8

Cost-utility analyses of intensive blood glucose and tight blood pressure control in type 2 diabetes (UKPDS 72).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-010-0224-8

Evaluation of the costs and outcomes from changes in risk factors in type 2 diabetes using the Cardiff stochastic simulation cost-utility model (DiabForecaster).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-010-0224-8

The CORE Diabetes Model: Projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-010-0224-8

Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-010-0224-8

Safety and efficacy of insulin glargine (HOE 901) versus NPH insulin in combination with oral treatment in Type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-010-0224-8

Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with Type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-010-0224-8

Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-010-0224-8

Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-010-0224-8

Impact of dosage frequency on patient compliance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-010-0224-8

Impact of dose frequency on compliance and health outcomes: a literature review (1966-2006).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-010-0224-8

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-010-0224-8

Mealtime treatment with insulin analog improves postprandial hyperglycemia and hypoglycemia in patients with non-insulin-dependent diabetes mellitus. Multicenter Insulin Lispro Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-010-0224-8

Exenatide: effect of injection time on postprandial glucose in patients with Type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-010-0224-8

A review of 20 years' experience with the NovoPen family of insulin injection devices

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-010-0224-8

Insulin glargine: an updated review of its use in the management of diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-010-0224-8

Improving treatment satisfaction and other patient-reported outcomes in people with type 2 diabetes: the role of once-daily insulin glargine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-010-0224-8

Empowering diabetes out-patients with structured education: short-term and long-term effects of functional insulin treatment on perceived control over diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-010-0224-8

Development and validation of the Diabetes Quality of Life Clinical Trial Questionnaire.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-010-0224-8

Development and validation of the insulin treatment satisfaction questionnaire.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-010-0224-8

Five weeks of treatment with the GLP-1 analogue liraglutide improves glycaemic control and lowers body weight in subjects with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-010-0224-8

A multicenter, open-label, randomized, two-period crossover trial comparing glycemic control, satisfaction, and preference achieved with a 31 gauge x 6 mm needle versus a 29 gauge x 12.7 mm needle in obese patients with diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-010-0224-8

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-010-0224-8

Clinical experience with exenatide in predominantly Asian and Pacific Islander patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-010-0224-8

Comparison of the rating scale and the standard gamble in measuring patient preferences for outcomes of gallstone disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-010-0224-8

A cost utility analysis of treatment options for gallstone disease: methodological issues and results

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-010-0224-8

Valuing temporary and chronic health states associated with breast screening.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-010-0224-8

Development of a brief measure to assess quality of life in obesity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-010-0224-8

The management of the obese diabetic patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-010-0224-8

Weight gain during insulin therapy in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-010-0224-8

Treatment of diabetes in patients with severe obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-010-0224-8

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-010-0224-8

Coping with Type II diabetes: the patient's perspective.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-010-0224-8

Assessing weight-related quality of life in obese persons with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-010-0224-8

Relationship between quality of life instruments, health state utilities, and willingness to pay in patients with asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-010-0224-8

Patients' health-related quality-of-life and health state values for motor neurone disease/amyotrophic lateral sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-010-0224-8

Comparison of the standard gamble, rating scale, AQLQ and SF-36 for measuring quality of life in asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-010-0224-8

Health state utilities in gastroesophageal reflux disease patients with heartburn: a study in Germany and Sweden

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-010-0224-8

Subjective health values of individuals with diabetes in Japan: comparison of utility values with the SF-36 scores

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-010-0224-8

Quality of life in epilepsy: comparison of four preference measures

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-010-0224-8

What value health?: A review of health state values used in early technology assessments for NICE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-010-0224-8

The 16-Item quick inventory of depressive symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-010-0224-8

Methodological issues of patient utility measurement. Experience from two clinical trials.

21 January 2018

1 reference

12 December 2020

Addressing dosing frequency in diabetes: a simple approach to improving adherence to therapy and clinical outcomes

1 reference

12 December 2020

United Kingdom Prospective Diabetes Study 24: a 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy. United Kingd

1 reference

12 December 2020

Health state utilities for childhood attention-deficit/hyperactivity disorder based on parent preferences in the United kingdom

1 reference

12 December 2020

Health state preference assessment in diabetic peripheral neuropathy

1 reference

12 December 2020

A computer simulation model of diabetes progression, quality of life, and cost

1 reference

12 December 2020

The standard gamble method: what is being measured and how it is interpreted

1 reference

12 December 2020

Treatment satisfaction and quality of life with insulin glargine plus insulin lispro compared with NPH insulin plus unmodified human insulin in individuals with type 1 diabetes

1 reference

12 December 2020

Reduction of postprandial hyperglycemia and frequency of hypoglycemia in IDDM patients on insulin-analog treatment. Multicenter Insulin Lispro Study Group.

1 reference

12 December 2020

Patient-assigned health state utilities for depression-related outcomes: differences by depression severity and antidepressant medications

1 reference

12 December 2020

Assessment of health state utilities for attention-deficit/hyperactivity disorder in children using parent proxy report

1 reference

12 December 2020

Discrepancies between chained and classic utilities induced by anchoring with occasional adjustments

1 reference

12 December 2020

Incorporating utility-based quality-of-life assessment measures in clinical trials. Two examples

1 reference

12 December 2020

Health utility estimation

1 reference

12 December 2020

Overview of patient compliance with medication dosing: a literature review

1 reference

12 December 2020

Utilities and disutilities for type 2 diabetes treatment-related attributes

1 reference

12 December 2020

Preferences for health outcomes and cost-utility analysis

1 reference

12 December 2020

Utilities and quality-adjusted life years

1 reference

12 December 2020

Systematic review and economic evaluation of a long-acting insulin analogue, insulin glargine

1 reference

12 December 2020

10.1007/S10198-010-0224-8

Identifiers

DOI

1 reference

16 February 2018

1 reference

16 February 2018